Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameNC Healthcare
Stock Code01518
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是北京領先的私立兒科醫療服務提供者,旗下以「新世紀醫療」品牌經營三間醫療機構,提供兒科及婦產科專科服務,並於二零一五年十二月開始提供醫院諮詢服務。
Listing Date2017-01-18
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京市西城區南禮士路56號
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座36樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.ncich.com.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 7.36 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2016-12-30 to 2017-01-11
Global Offering Shares120,000,000 shares
HK Public Offer Shares (Initial)12,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)108,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO480,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share16.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 883,200,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 145.5M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +6574%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣67.2百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2013201420152016-09
Revenue 238,770249,013258,196340,026
Cost of sales -88,981-105,118-117,686-176,414
Gross profit 149,789143,895140,510163,612
Other income and gains, net 27136125-17,927
Selling and distribution expenses -7,272-11,278-10,612-13,811
Administrative expenses -32,883-34,702-38,312-63,935
Operating profit 109,66198,05191,71167,939
Net finance costs -1,087-2,647-273961
Profit before tax 110,748100,69891,98466,978
Income tax expense -28,038-26,383-24,789-23,840
Profit for the year 82,71074,31567,19543,138
Profit attributable to owners 53,56646,70540,90319,193
Balance Sheet
Item 2013201420152016-09
Cash and cash equivalents 128,959120,63981,231151,871
Trade and bills receivables 6,9716,56712,1937,987
Inventories 4,7833,3204,6256,281
Total current assets 146,636135,094126,112206,522
Total assets 166,636155,430532,063600,530
Total current liabilities 48,63857,968165,507167,913
Total liabilities 48,63857,968564,457532,290
Total equity 117,99897,462-32,39468,240
Equity attributable to owners 79,78663,088-43,50127,285
Interest-bearing borrowings 0030,00024,990
Cash Flow Statement
Item 2013201420152016-09
Net cash from operating activities 87,70584,56079,07172,112
Net cash from investing activities -4,646-3,029-19,1227,215
Net cash from financing activities -80,091-89,851-99,357-8,687
Net increase in cash 2,968-8,320-39,40870,640
Purchase of PP&E -2,854-3,248-5,694-10,552
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 7.35
First Day OpenHK$ 7.5
First Day Change-0.14%
First Day Volume12546500.0
First Day Turnover91943300.0
Use of Proceeds
1、39.4百萬港元(相當于所得款項凈額的5.0%)將用于在北京興建一座遠程醫療診斷中心; 2、39.4百萬港元(相當于所得款項凈額的5.0%)將用于翻新及提升我們于北京的一間手術中心; 3、157.7百萬港元(相當于所得款項凈額的20.0%)將用于在北京開設一家新醫院以提供專業兒科及婦產科服務以及在北京開設兩家診所以主要提供門診服務; 4、157.7百萬港元(相當于所得款項凈額的20.0%)將用于在北京以外的一線城市開設一間新醫院及兩間診所; 5、315.5百萬港元(相當于所得款項凈額的40.0%)將用于收購一線城市(包括北京)的一間醫院及五間診所; 6、78.9百萬港元(相當于所得款項凈額的10.0%)將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 BOCI ASIA LIMITED CE AET863 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 BOCI ASIA LIMITED CE AET863 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 CNCB (Cayman) NCH LP 175,904,000 HKD — 4.98% — 6 months 2017-07-18
2 Janchor Partners Pan-Asian Master Fund 155,093,600 HKD — 4.39% — 6 months 2017-07-18
3 中国人寿再保险有限责任公司 232,642,240 HKD — 6.59% — 6 months 2017-07-18

Directors & Management

PositionChinese nameEnglish Name
ChairmanJason ZHOU—
Company Secretary賈曉鋒、黃秀萍—
No director data available.

Major Shareholders

Major Shareholders & HoldingsZhou先生持有45.0%、梁女士持有12.0%、鼎暉孚紀持有6.2%、鼎暉孚怡持有6.2%、安怡和康持有6.6%、甘鋒女士持有5.0%、國禾嘉華持有4.1%。
About this page

This page shows NC Healthcare (01518) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect